ARNA:NAS (USA) Also trade in: Germany UK

Arena Pharmaceuticals Inc

$ 43.18 -1.75 (-3.89%)
Volume: 878,532 Avg Vol (1m): 439,837
Market Cap $: 2.14 Bil Enterprise Value $: 1.74 Bil
P/E (TTM): 0.00 P/B: 3.52
Earnings Power Value -48.17
Net Current Asset Value 7.69
Tangible Book 12.26
Projected FCF -3.31
Median P/S Value 9.97
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
YTD (-%)

Financial Strength : 6/10

Current vs industry vs history
Cash-to-Debt 8.46
Equity-to-Asset 0.88
Debt-to-Equity 0.09
Debt-to-EBITDA -0.41
Piotroski F-Score 4
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 14.53
DISTRESS
GREY
SAFE
Beneish M-Score 0.42
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC -49.08%
WACC 11.79%

Profitability & Growth : 2/10

Current vs industry vs history
Operating Margin % -809.90
Net Margin % -163.60
ROE % -5.91
ROA % -4.97
ROC (Joel Greenblatt) % -477.94
3-Year Total Revenue Growth Rate 10.30
N/A
3-Year Total EBITDA Growth Rate -9.50
3-Year EPS w/o NRI Growth Rate 49.00

» ARNA's 30-Y Financials

Financials (Next Earnings Date: 2019-05-08)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:ARNA

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325412    SIC : 2834
Compare NAS:CORT SZSE:002030 NAS:ESPR NAS:INSM NAS:ACAD NAS:ICPT BOM:539268 XMCE:ALM NYSE:CBM NAS:AIMT SZSE:002287 NAS:GBT NAS:ENTA HKSE:06826 NAS:MYOK XKRX:095700 NAS:DNLI LSE:GNS NAS:XLRN SZSE:002653
Traded in other countries RN3N.Germany 0S54.UK
Address 6154 Nancy Ridge Drive, San Diego, CA, USA, 92121
Arena Pharmaceuticals is a biotechnology company targeting G-protein-coupled receptors. The company has one internally discovered drug, lorcaserin, which has been approved and is marketed in the U.S. and South Korea to target weight management. It is commercialized under the brand name Belviq. The company is collaborating with Eisai to market Belviq in other countries. It has a presence in Europe through its Swiss subsidiary, Arena GmbH. The company's pipeline contains drugs targeting autoimmune diseases, vascular diseases, thrombotic diseases, dementia-associated psychosis, nervous system issues, and pain.

Ratios

Current vs industry vs history
Forward PE Ratio 4.03
N/A
PB Ratio 3.52
PS Ratio 116.09
EV-to-EBIT -13.06
EV-to-EBITDA -13.47
EV-to-Revenue 96.98
Current Ratio 15.40
Quick Ratio 15.40
Days Inventory 113.61
Days Sales Outstanding 103.30
Days Payable 513.65

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -24.60

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 3.52
Price-to-Median-PS-Value 4.42
Earnings Yield (Joel Greenblatt) % -7.59

More Statistics

Revenue (TTM) (Mil) $ 17.97
EPS (TTM) $ -0.8
Beta 1.57
Volatility % 45.91
52-Week Range $ 31.97 - 51.63
Shares Outstanding (Mil) 39.28

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 4
Positive ROA N
Positive CFROA N
Higher ROA yoy Y
CFROA > ROA N
Lower Leverage yoy Y
Higher Current Ratio yoy Y
Less Shares Outstanding yoy N
Higher Gross Margin yoy Y
Higher Asset Turnover yoy N